STB
TERN

S&T Bank’s Terns Pharmaceuticals TERN Stock Holding History

S&T Bank’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-10,000
Closed -$104K – 142
2021
Q3 		$104K Buy
+10,000
New +$104K 0.02% 127

Other funds holding TERN

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
AC
Antara Capital New York $30.2K AUM 5.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

S&T Bank's TERN Position: Q4 2021 in Review

S&T Bank sold out of Terns Pharmaceuticals (TERN) in Q4 2021, closing a stake of 10,000 shares — an estimated $104K sold.

S&T Bank first reported a position in TERN in Q3 2021 and held it in 1 quarter. The position peaked at $104K in Q3 2021. 37 funds tracked by Wall St. Rank hold TERN as of Q4 2021.

  • S&T Bank reported no remaining Terns Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
  • S&T Bank sold 10,000 Terns Pharmaceuticals shares in Q4 2021, an estimated $104K.
  • S&T Bank first reported a position in Terns Pharmaceuticals in Q3 2021 and held it in 1 quarter.
  • S&T Bank's Terns Pharmaceuticals position peaked at $104K in Q3 2021.
  • 37 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2021.

Based on S&T Bank's 13F filing for Q4 2021, filed 14 Feb 2022.